Early assessment predicts long-term efficacy of HIV-1 antiretroviral therapy

November 22, 2001

N.B. Please note that if you are outside North America please note that the embargo for Lancet press material is 0001 hours UK Time Friday 23 November 2001.

A study in this week's issue of THE LANCET highlights how very early (one week) assessment can reliably predict the long-term effectiveness of antiretroviral therapy for HIV-1.

Early assessment of antiretroviral drug efficacy is important for the prevention of the emergence of drug-resistant virus and unnecessary exposure to ineffective and toxic drugs. Current US guidelines for changing therapy are based on measurements of plasma HIV-1 RNA concentrations 4 or 8 weeks after the start of treatment. Michael Polis, Dimiter Dimitrov, and colleagues from the US National Institute of Allergy and Infectious Diseases, and the National Cancer Institute, Bethesda, USA, investigated whether it was possible to assess drug efficacy from measurements of plasma HIV-1 concentrations made during the first week on therapy.

124 HIV-1-infected patients being treated for the first time with a protease inhibitor had their virus decay analysed for the first 12 weeks after the start of antiretroviral therapy. Patients with a continuous decline of HIV-1 concentrations and in whom HIV-1 was either undetectable or had declined substantially (by more than 1.5 log at 12 weeks) were defined as good responders; the rest were poor responders.

The virus decay rate at 6 days after the start of antiretroviral therapy was associated with changes in HIV-1 concentrations at 4, 8, and 12 weeks. Reduction in plasma HIV-1 of less than 0.72 log by day 6 after initiation of therapy predicted poor long-term responses in more than 99% of patients.

Dimiter Dimitrov comments: "These results suggest that changes in HIV-1 concentration at day 6 after treatment initiation are major correlates of longer-term virological responses. They offer a very early measure of individual long-term responses, suggesting that treatment could be optimised after only a few days of therapy."
-end-
Contact: Dr Michael Polis, c/o Jeff Minerd, Office of Communications and Public Liaison, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Building 31, Room 7A-50, 31 Center Drive, MSC 2520, Bethesda, MD 20892, USA; T) +1 301 496 5719; F) +1 301 402 0120; E) jminerd@niaid.nih.gov

Professor Dimiter S Dimitrov, Laboratory of Experimental and Computational Biology, Center for Cancer Research, NCI-Frederick, NIH, Bldg 469, Rm 246, PO Box B, Miller Drive, Frederick, MD 21702-1201, USA; T) +1 301 846 1352; F) +1 301 846 6189; E) dimitrov@ncifcrf.gov

Lancet

Related Antiretroviral Therapy Articles from Brightsurf:

Antiretroviral therapy can't completely stop accelerated cell aging seen in HIV
Untreated HIV infection is linked with epigenetic changes that suggest rapid aging.

Antiretroviral therapy fails to treat one-third of HIV patients in Malawi hospital
Antiretroviral therapy (ART) failure and drug resistance are extremely common in patients living with HIV who are admitted to hospital in Malawi, according to new research published in Lancet HIV.

Sugar-based signature identifies T cells where HIV hides despite antiretroviral therapy
Wistar scientists may have discovered a new way of identifying and targeting hidden HIV viral reservoirs during treatment with antiretroviral therapy (ART).

HIV reservoirs in humans: Immediate antiretroviral therapy makes them 100 times smaller
Thanks to an unprecedented access to blood, and biopsies of rectums and lymph nodes of people at the earliest stages of HIV infection, an international team of researchers at the University of Montreal Hospital Research Centre (CRCHUM), the US Military HIV Research Program and the Thai Red Cross AIDS Research Centre has shown that the first established reservoirs are still 'sensitive' during these early stages and could be downsized about 100 times upon immediate ART initiation.

Changes in the cost over tine of HIV antiretroviral therapy in US
Researchers calculated the average cost of recommended initial HIV antiretroviral therapy (ART) regimens in the US from 2012 to 2018 and analyzed how this cost has changed over the years.

Study suggests antiretroviral therapy does not restore disease immunity
A study led by researchers from SUNY Downstate Health Sciences University and Oregon Health & Science University, published in the Journal of Infectious Diseases, showed that, despite successful antiretroviral therapy (ART), antigen specific memory to vaccinations that occurred before HIV infection did not recover, even after immune reconstitution.

Immediate treatment with antiretroviral therapy helps infants with HIV
As part of an international collaborative effort, investigators from Brigham and Women's Hospital conducted immunological and virological testing on newborns in Botswana, finding that initiating antiretroviral therapy immediately, rather than waiting a few weeks, provided measurable benefits for infants born with HIV.

HIV may affect the brain despite ongoing antiretroviral therapy
HIV-positive patients are living longer thanks to combination antiretroviral therapy (cART), but the virus can remain in some tissues, preventing a total cure.

Being HIV positive and staying on antiretroviral therapy in Africa: A systematic review
An international team of researchers have carried out a review of the evidence examining what influences people who are HIV positive to go to health services and then stay on antiretroviral drugs in Africa.

Benefits of early antiretroviral therapy in HIV-infected children
The initial findings of the ANRS CLEAC study coordinated by Pierre Frange (Hôpital Necker -- AP-HP), help define the immunological and virological benefits of early antiretroviral therapy in HIV-infected children living in France.

Read More: Antiretroviral Therapy News and Antiretroviral Therapy Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.